David Scott Batey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Scott Batey has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Rebecca Schnall
Columbia University School of Nursing
11 shared publications - Emma Sophia Kay
Department of Acute, Chronic, and Continuing Care, Birmingham School of Nursing, University of Alabama, Birmingham, USA
9 shared publications - Asa Radix
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, USA
5 shared publications - Maeve Brin
School of Nursing, Columbia University, New York, NY, United States
5 shared publications - Michael J. Mugavero
The University of Alabama at Birmingham Heersink School of Medicine
4 shared publications - Cynthia R. Pearson
Indigenous Wellness Research Institute, School of Social Work, University of Washington, Seattle, USA
3 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
CHAMPS+: Protocol for a Randomized Trial of a CHW-Delivered mHealth Intervention to Improve Viral Suppression in the U.S. Deep South
Viral suppression (VS) disparities persist among persons living with HIV in the U.S. Deep South because of structural barriers and disengagement from care. Community health workers and mobile health (mHealth) interventions may address multilevel challenges, yet real-world evidence is limited. The aim of our study is to evaluate effectiveness and implementation of CHAMPS+, a CHW-delivered mHealth intervention to improve VS. CHAMPS+ is a multisite randomized controlled trial with mixed-method implementation evaluation. A total of 420 virally unsuppressed or out-of-care adults with HIV in Alabama (AL), Louisiana (LA), and Mississippi (MS) are randomized to a 6-month CHW-delivered program supported by WiseApp and electronic adherence monitoring or standard care. Implementation is assessed using RE-AIM. The primary outcome is VS at 6 months; secondary outcomes include medication adherence and psychosocial mediators. The trial will generate evidence on the clinical effectiveness and real-world implementation of a scalable CHW-mHealth intervention in Ending the HIV Epidemic priority jurisdictions.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
CHAMPS+: Protocol for a Randomized Trial of a CHW-Delivered mHealth Intervention to Improve Viral Suppression in the U.S. Deep South
Viral suppression (VS) disparities persist among persons living with HIV in the U.S. Deep South because of structural barriers and disengagement from care. Community health workers and mobile health (mHealth) interventions may address multilevel challenges, yet real-world evidence is limited. The aim of our study is to evaluate effectiveness and implementation of CHAMPS+, a CHW-delivered mHealth intervention to improve VS. CHAMPS+ is a multisite randomized controlled trial with mixed-method implementation evaluation. A total of 420 virally unsuppressed or out-of-care adults with HIV in Alabama (AL), Louisiana (LA), and Mississippi (MS) are randomized to a 6-month CHW-delivered program supported by WiseApp and electronic adherence monitoring or standard care. Implementation is assessed using RE-AIM. The primary outcome is VS at 6 months; secondary outcomes include medication adherence and psychosocial mediators. The trial will generate evidence on the clinical effectiveness and real-world implementation of a scalable CHW-mHealth intervention in Ending the HIV Epidemic priority jurisdictions.
- 5 October 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Multilevel Barriers and Facilitators to HIV Care Engagement Among Virally Unsuppressed People Living With HIV in the U.S. Deep South: A Qualitative Study
The U.S. South experiences disproportionate HIV-related morbidity and persistently lower viral suppression rates. Achieving Ending the HIV Epidemic goals requires understanding multilevel influences on care engagement among virally unsuppressed people living with HIV. We conducted in-depth qualitative interviews with 30 virally unsuppressed people living with HIV receiving care across Alabama, Louisiana, and Mississippi. Guided by the Modified Social Ecological Model, we examined individual, interpersonal, clinic, community, and policy-level factors shaping engagement and antiretroviral therapy adherence. Participants described intersecting structural and psychosocial barriers, including financial insecurity, transportation challenges, depression, and internalized stigma. Social networks functioned as both support and stigma, particularly within family and faith contexts. Clinics served as critical anchors when providing confidential, holistic services addressing social needs, although inefficiencies and resource constraints disrupted continuity. Persistent discrimination, restrictive policies, funding instability, and HIV criminalization further threatened engagement, underscoring the need for multilevel interventions to improve viral suppression.
- 5 October 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Multilevel Barriers and Facilitators to HIV Care Engagement Among Virally Unsuppressed People Living With HIV in the U.S. Deep South: A Qualitative Study
The U.S. South experiences disproportionate HIV-related morbidity and persistently lower viral suppression rates. Achieving Ending the HIV Epidemic goals requires understanding multilevel influences on care engagement among virally unsuppressed people living with HIV. We conducted in-depth qualitative interviews with 30 virally unsuppressed people living with HIV receiving care across Alabama, Louisiana, and Mississippi. Guided by the Modified Social Ecological Model, we examined individual, interpersonal, clinic, community, and policy-level factors shaping engagement and antiretroviral therapy adherence. Participants described intersecting structural and psychosocial barriers, including financial insecurity, transportation challenges, depression, and internalized stigma. Social networks functioned as both support and stigma, particularly within family and faith contexts. Clinics served as critical anchors when providing confidential, holistic services addressing social needs, although inefficiencies and resource constraints disrupted continuity. Persistent discrimination, restrictive policies, funding instability, and HIV criminalization further threatened engagement, underscoring the need for multilevel interventions to improve viral suppression.
- Open Access
- 4 July 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-7
Designing For Choice In HIV Prevention: Translating Multi-Stakeholder Evidence Into A Patient-Facing mHealth Ecosystem For Prep
- 4 July 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-7
Open AccessDesigning For Choice In HIV Prevention: Translating Multi-Stakeholder Evidence Into A Patient-Facing mHealth Ecosystem For Prep
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1580-1590
The Potential Impact of Ending the Ryan White HIV/AIDS Program on HIV Incidence: A Simulation Study in 31 U.S. Cities
With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States. To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months. A compartmental HIV transmission model was used to simulate epidemics and Ryan White service use. The researchers calibrated model transmission to surveillance data from the U.S. Centers for Disease Control and Prevention in each city and calibrated the number of Ryan White clients to program reports. Ryan White clinic directors and administrators were surveyed to estimate how many clients would lose viral suppression if services stopped. Simulated HIV epidemics in 31 high-burden U.S. cities. Through 2030. Not applicable. The researchers projected HIV incidence under the following 4 scenarios: continued services, cessation in July 2025, interruption until January 2027, and interruption until January 2029. Projected excess HIV infections from 2025 to 2030. Ending Ryan White services in July 2025 could result in 75 436 additional infections (95% credible interval [CrI], 19 251 to 134 175 infections) through 2030-a 49% (95% CrI, 12% to 86%) increase. Increases ranged from 9% (Riverside, California) to 110% (Baltimore, Maryland). Interruptions of 18 and 42 months yielded 19% and 38% more infections, respectively. A "conservative" analysis with lower simulated loss of suppression from observational studies projected 34 051 excess infections (95% CrI, 23 902 to 45 147 infections). The loss of suppression if Ryan White services end may be misestimated by survey responses and observational studies. Disrupting Ryan White services could sharply increase HIV incidence, highlighting their critical public health value. None.
- 24 September 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 191, 148-154
Pro-inflammatory biomarkers associated with depression severity among adults with HIV in New York City
- 24 September 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 191, 148-154
Pro-inflammatory biomarkers associated with depression severity among adults with HIV in New York City
- Open Access
The Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 18 States
Background Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under three scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results If CDC funding for HIV tests were to end on October 1, 2025, we project 12,719 additional HIV infections across 18 states by 2030 (95% Credible Interval 4,547 to 21,896) – an increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0 to 4.7%) to a 29.9 increase in Louisiana (9.4 to 59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDC’s HIV testing activities in curbing the spread of HIV in the US. Summary A complete cessation of CDC-funded HIV testing could cause a 10% increase in infections by 2030 across 18 U.S. states, with this impact disproportionately affecting rural states. Mobilizing access to alternative HIV testing would be critical to mitigating this impact.
Open AccessThe Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 18 States
Background Timely HIV diagnosis and treatment is critical to preventing transmission. The US Centers for Disease Control and Prevention (CDC) provides funding for HIV testing to local health departments and community organizations. We sought to estimate the number of additional HIV infections that would result from ending or interrupting CDC funding for HIV tests in US states. Methods We used a validated model of HIV transmission to simulate HIV epidemics in 18 US states. We projected incidence forward under three scenarios where all CDC-funded HIV testing ends in October 2025 and (1) never resumes, (2) returns to previous levels between January and December 2027, and (3) returns from January to December 2029. We calculated the excess incident HIV infections compared to a scenario where CDC-funded testing continues uninterrupted. Results If CDC funding for HIV tests were to end on October 1, 2025, we project 12,719 additional HIV infections across 18 states by 2030 (95% Credible Interval 4,547 to 21,896) – an increase of 10%. The projected effects varied by state, ranging from a 2.7% increase in Washington (1.0 to 4.7%) to a 29.9 increase in Louisiana (9.4 to 59.9%). States that perform more CDC-funded tests and states with more rural HIV epidemics were projected to see greater rises in incidence. Conclusions Disruptions to CDC-funded HIV testing would substantially increase new infections, particularly in states with more rural epidemics. These findings demonstrate the value of the CDC’s HIV testing activities in curbing the spread of HIV in the US. Summary A complete cessation of CDC-funded HIV testing could cause a 10% increase in infections by 2030 across 18 U.S. states, with this impact disproportionately affecting rural states. Mobilizing access to alternative HIV testing would be critical to mitigating this impact.
- 6 June 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 138, 109221
Use of cognitive interviews to develop PrEP education for men in New York and Alabama
- 6 June 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 138, 109221
Use of cognitive interviews to develop PrEP education for men in New York and Alabama
- 4 April 2025
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (3) , 284-296
Pre-exposure Prophylaxis Providers in Birmingham, Alabama, and New York City, New York, Identify Critical Barriers to Newer Pre-exposure Prophylaxis Strategies: A Mixed Methods Study
Young Black and Latino men who have sex with men are disproportionately affected by the U.S. HIV Epidemic, yet pre-exposure prophylaxis (PrEP) uptake remains low. To understand barriers and facilitators to PrEP uptake and persistence, we used a concurrent mixed methods design (quantitative: online surveys, n = 19; qualitative: individual interviews, n = 15) from providers (e.g., nurse practitioners, clinicians, and social workers) at 4 clinics providing PrEP services in Birmingham, Alabama and New York City. Although all providers were comfortable prescribing daily oral PrEP, they had concerns about on-demand PrEP (e.g., complex dosing schedule) and injectable PrEP (e.g., insurance barriers). Provider training is needed to address barriers to providing PrEP modalities beyond daily oral PrEP and increase uptake among young Black and Latino men who have sex with men. Additionally, in order to increase uptake of injectable PrEP, rising PrEP costs due to changes in the 340B Drug Pricing Program will need to be addressed.
- 4 April 2025
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (3) , 284-296
Pre-exposure Prophylaxis Providers in Birmingham, Alabama, and New York City, New York, Identify Critical Barriers to Newer Pre-exposure Prophylaxis Strategies: A Mixed Methods Study
Young Black and Latino men who have sex with men are disproportionately affected by the U.S. HIV Epidemic, yet pre-exposure prophylaxis (PrEP) uptake remains low. To understand barriers and facilitators to PrEP uptake and persistence, we used a concurrent mixed methods design (quantitative: online surveys, n = 19; qualitative: individual interviews, n = 15) from providers (e.g., nurse practitioners, clinicians, and social workers) at 4 clinics providing PrEP services in Birmingham, Alabama and New York City. Although all providers were comfortable prescribing daily oral PrEP, they had concerns about on-demand PrEP (e.g., complex dosing schedule) and injectable PrEP (e.g., insurance barriers). Provider training is needed to address barriers to providing PrEP modalities beyond daily oral PrEP and increase uptake among young Black and Latino men who have sex with men. Additionally, in order to increase uptake of injectable PrEP, rising PrEP costs due to changes in the 340B Drug Pricing Program will need to be addressed.
- Open Access
- 2 April 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e67997
A Remote Intervention Based on mHealth and Community Health Workers for Antiretroviral Therapy Adherence in People With HIV: Pilot Randomized Controlled Trial
Background: Despite the availability of antiretroviral therapy (ART), only 66% of people with HIV in the United States achieve viral suppression, largely due to suboptimal ART adherence. Barriers such as limited access to care and forgetfulness impact adherence rates, which must be maintained at ≥95% to prevent viral load rebound. Combination interventions leveraging community health worker (CHW) support and mobile health (mHealth) technologies have the potential to overcome previously identified barriers and provide cost-effective support for improving adherence and viral suppression outcomes in people with HIV. Objective: This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of remote delivery of the Community Health Worker and mHealth to Improve Viral Suppression (CHAMPS) intervention, combining the WiseApp, CHW support, and the CleverCap smart pill bottle. A secondary aim was to gather participants’ feedback on the usability of the app and pill bottle as well as to better understand their experiences with remote study procedures. Methods: This mixed methods pilot study involved 40 participants with HIV, who were randomly assigned to a control group (n=20, 50%) or the CHAMPS intervention (n=20, 50%) over 3 months. The intervention group participated in up to 12 sessions with CHWs and used the WiseApp, paired with a CleverCap smart pill bottle, to support ART adherence. Remote baseline and follow-up visits were conducted via Zoom and included surveys measuring adherence, self-efficacy, and usability (measured by Health Information Technology Usability Evaluation Scale [Health-ITUES] and Poststudy System Usability Questionnaire [PSSUQ]). Semistructured interviews explored participants’ experiences with the intervention. Thematic analysis was used to identify key facilitators and barriers based on the Mobile Health Technology Acceptance Model. Results: Remote delivery of the CHAMPS intervention was feasible, with high usability ratings for both the WiseApp and CleverCap (overall scores on Health-ITUES: mean 4.35, SD 0.58 and PSSUQ: mean 2.04, SD 1.03). In the intervention group, there were nonsignificant improvements in self-reported adherence scores (P=.29) and in self-efficacy scores (P=.07). The adjusted odds ratio for achieving undetectable viral load in the intervention group compared to the control group was 3.01 (95% CI –1.59 to 4.12), indicating a medium effect size in favor of the intervention. Overall study retention was 75% (30/40), with higher retention in the control group. Participants valued the flexibility of remote study procedures, particularly Zoom-based study visits and mailed blood sample kits. Qualitative feedback highlighted the intervention’s acceptability and ability to overcome logistical barriers. Conclusions: The remote CHAMPS pilot study demonstrated the feasibility and acceptability of combining mHealth tools with CHW support to promote medication adherence among people with HIV. While further optimization is needed to enhance its impact, this intervention shows potential for improving health outcomes in diverse underserved populations. Trial Registration: ClinicalTrials.gov NCT05938413; https://clinicaltrials.gov/study/NCT05938413
- 2 April 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e67997
Open AccessA Remote Intervention Based on mHealth and Community Health Workers for Antiretroviral Therapy Adherence in People With HIV: Pilot Randomized Controlled Trial
Background: Despite the availability of antiretroviral therapy (ART), only 66% of people with HIV in the United States achieve viral suppression, largely due to suboptimal ART adherence. Barriers such as limited access to care and forgetfulness impact adherence rates, which must be maintained at ≥95% to prevent viral load rebound. Combination interventions leveraging community health worker (CHW) support and mobile health (mHealth) technologies have the potential to overcome previously identified barriers and provide cost-effective support for improving adherence and viral suppression outcomes in people with HIV. Objective: This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of remote delivery of the Community Health Worker and mHealth to Improve Viral Suppression (CHAMPS) intervention, combining the WiseApp, CHW support, and the CleverCap smart pill bottle. A secondary aim was to gather participants’ feedback on the usability of the app and pill bottle as well as to better understand their experiences with remote study procedures. Methods: This mixed methods pilot study involved 40 participants with HIV, who were randomly assigned to a control group (n=20, 50%) or the CHAMPS intervention (n=20, 50%) over 3 months. The intervention group participated in up to 12 sessions with CHWs and used the WiseApp, paired with a CleverCap smart pill bottle, to support ART adherence. Remote baseline and follow-up visits were conducted via Zoom and included surveys measuring adherence, self-efficacy, and usability (measured by Health Information Technology Usability Evaluation Scale [Health-ITUES] and Poststudy System Usability Questionnaire [PSSUQ]). Semistructured interviews explored participants’ experiences with the intervention. Thematic analysis was used to identify key facilitators and barriers based on the Mobile Health Technology Acceptance Model. Results: Remote delivery of the CHAMPS intervention was feasible, with high usability ratings for both the WiseApp and CleverCap (overall scores on Health-ITUES: mean 4.35, SD 0.58 and PSSUQ: mean 2.04, SD 1.03). In the intervention group, there were nonsignificant improvements in self-reported adherence scores (P=.29) and in self-efficacy scores (P=.07). The adjusted odds ratio for achieving undetectable viral load in the intervention group compared to the control group was 3.01 (95% CI –1.59 to 4.12), indicating a medium effect size in favor of the intervention. Overall study retention was 75% (30/40), with higher retention in the control group. Participants valued the flexibility of remote study procedures, particularly Zoom-based study visits and mailed blood sample kits. Qualitative feedback highlighted the intervention’s acceptability and ability to overcome logistical barriers. Conclusions: The remote CHAMPS pilot study demonstrated the feasibility and acceptability of combining mHealth tools with CHW support to promote medication adherence among people with HIV. While further optimization is needed to enhance its impact, this intervention shows potential for improving health outcomes in diverse underserved populations. Trial Registration: ClinicalTrials.gov NCT05938413; https://clinicaltrials.gov/study/NCT05938413
- Open Access
- 25 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
A Remote Intervention Based on mHealth and Community Health Workers for Antiretroviral Therapy Adherence in People With HIV: Pilot Randomized Controlled Trial (Preprint)
BACKGROUND Despite the availability of antiretroviral therapy (ART), only 66% of people with HIV in the United States achieve viral suppression, largely due to suboptimal ART adherence. Barriers such as limited access to care and forgetfulness impact adherence rates, which must be maintained at ≥95% to prevent viral load rebound. Combination interventions leveraging community health worker (CHW) support and mobile health (mHealth) technologies have the potential to overcome previously identified barriers and provide cost-effective support for improving adherence and viral suppression outcomes in people with HIV. OBJECTIVE This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of remote delivery of the Community Health Worker and mHealth to Improve Viral Suppression (CHAMPS) intervention, combining the WiseApp, CHW support, and the CleverCap smart pill bottle. A secondary aim was to gather participants’ feedback on the usability of the app and pill bottle as well as to better understand their experiences with remote study procedures. METHODS This mixed methods pilot study involved 40 participants with HIV, who were randomly assigned to a control group (n=20, 50%) or the CHAMPS intervention (n=20, 50%) over 3 months. The intervention group participated in up to 12 sessions with CHWs and used the WiseApp, paired with a CleverCap smart pill bottle, to support ART adherence. Remote baseline and follow-up visits were conducted via Zoom and included surveys measuring adherence, self-efficacy, and usability (measured by Health Information Technology Usability Evaluation Scale [Health-ITUES] and Poststudy System Usability Questionnaire [PSSUQ]). Semistructured interviews explored participants’ experiences with the intervention. Thematic analysis was used to identify key facilitators and barriers based on the Mobile Health Technology Acceptance Model. RESULTS Remote delivery of the CHAMPS intervention was feasible, with high usability ratings for both the WiseApp and CleverCap (overall scores on Health-ITUES: mean 4.35, SD 0.58 and PSSUQ: mean 2.04, SD 1.03). In the intervention group, there were nonsignificant improvements in self-reported adherence scores (P=.29) and in self-efficacy scores (P=.07). The adjusted odds ratio for achieving undetectable viral load in the intervention group compared to the control group was 3.01 (95% CI –1.59 to 4.12), indicating a medium effect size in favor of the intervention. Overall study retention was 75% (30/40), with higher retention in the control group. Participants valued the flexibility of remote study procedures, particularly Zoom-based study visits and mailed blood sample kits. Qualitative feedback highlighted the intervention’s acceptability and ability to overcome logistical barriers. CONCLUSIONS The remote CHAMPS pilot study demonstrated the feasibility and acceptability of combining mHealth tools with CHW support to promote medication adherence among people with HIV. While further optimization is needed to enhance its impact, this intervention shows potential for improving health outcomes in diverse underserved populations. CLINICALTRIAL ClinicalTrials.gov NCT05938413; https://clinicaltrials.gov/study/NCT05938413
- 25 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Remote Intervention Based on mHealth and Community Health Workers for Antiretroviral Therapy Adherence in People With HIV: Pilot Randomized Controlled Trial (Preprint)
BACKGROUND Despite the availability of antiretroviral therapy (ART), only 66% of people with HIV in the United States achieve viral suppression, largely due to suboptimal ART adherence. Barriers such as limited access to care and forgetfulness impact adherence rates, which must be maintained at ≥95% to prevent viral load rebound. Combination interventions leveraging community health worker (CHW) support and mobile health (mHealth) technologies have the potential to overcome previously identified barriers and provide cost-effective support for improving adherence and viral suppression outcomes in people with HIV. OBJECTIVE This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of remote delivery of the Community Health Worker and mHealth to Improve Viral Suppression (CHAMPS) intervention, combining the WiseApp, CHW support, and the CleverCap smart pill bottle. A secondary aim was to gather participants’ feedback on the usability of the app and pill bottle as well as to better understand their experiences with remote study procedures. METHODS This mixed methods pilot study involved 40 participants with HIV, who were randomly assigned to a control group (n=20, 50%) or the CHAMPS intervention (n=20, 50%) over 3 months. The intervention group participated in up to 12 sessions with CHWs and used the WiseApp, paired with a CleverCap smart pill bottle, to support ART adherence. Remote baseline and follow-up visits were conducted via Zoom and included surveys measuring adherence, self-efficacy, and usability (measured by Health Information Technology Usability Evaluation Scale [Health-ITUES] and Poststudy System Usability Questionnaire [PSSUQ]). Semistructured interviews explored participants’ experiences with the intervention. Thematic analysis was used to identify key facilitators and barriers based on the Mobile Health Technology Acceptance Model. RESULTS Remote delivery of the CHAMPS intervention was feasible, with high usability ratings for both the WiseApp and CleverCap (overall scores on Health-ITUES: mean 4.35, SD 0.58 and PSSUQ: mean 2.04, SD 1.03). In the intervention group, there were nonsignificant improvements in self-reported adherence scores (P=.29) and in self-efficacy scores (P=.07). The adjusted odds ratio for achieving undetectable viral load in the intervention group compared to the control group was 3.01 (95% CI –1.59 to 4.12), indicating a medium effect size in favor of the intervention. Overall study retention was 75% (30/40), with higher retention in the control group. Participants valued the flexibility of remote study procedures, particularly Zoom-based study visits and mailed blood sample kits. Qualitative feedback highlighted the intervention’s acceptability and ability to overcome logistical barriers. CONCLUSIONS The remote CHAMPS pilot study demonstrated the feasibility and acceptability of combining mHealth tools with CHW support to promote medication adherence among people with HIV. While further optimization is needed to enhance its impact, this intervention shows potential for improving health outcomes in diverse underserved populations. CLINICALTRIAL ClinicalTrials.gov NCT05938413; https://clinicaltrials.gov/study/NCT05938413